Clinical Trial

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

Study acronym: DUPI REDUCE
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-21; most recent amendment 2025-10-06.
Status change: Not Yet Recruiting → Recruiting 2023-08-30
Trial Details
NCT Number NCT06004986
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Erasmus Medical Center, Prothya Biosolutions
Conditions Atopic Dermatitis, Atopic Dermatitis Eczema
Enrollment 216 participants
Start Date 2023-08-14
Primary Completion 2025-10-01 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-08